EUVIMEDEUVIMED entdecken
Open Access

Personalized management of acenocoumarol dosage using eGFR: Analysis of INR data in a cohort of 204 patients

Dzhem Farandzha, Vasil Velchev, Dobri Hazarbasanov

Int. Journal of Clinical Pharmacology and Therapeutics · 2025

DOI: 10.5414/cp204882 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2025. Verfasst von Dzhem Farandzha und 2 weiteren Autor:innen. Hauptthemen laut MEDLINE: Acenocoumarol, Glomerular Filtration Rate, Anticoagulants, International Normalized Ratio. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Acenocoumarol is a widely used vitamin K antagonist, particularly in European countries. While age and body metrics are known to influence dose requirements, the role of renal function in guiding acenocoumarol dosage remains underexplored. AIMS: The primary aim of this study was to investigate the relationship between renal function and the weekly dose of acenocoumarol required to maintain therapeutic international normalized ratio (INR) levels. MATERIALS AND METHODS: We analyzed 425 INR measurements from 204 adult patients receiving acenocoumarol, stratified by target INR ranges of 2.00 - 3.00 and 2.50 - 3.50. Renal function was assessed using the body surface area (BSA)-adjusted chronic kidney disease-epidemiology (CKD-EPI) 2021 formula. Weekly acenocoumarol doses were evaluated in relation to age, sex, estimated glomerular filtration rate (eGFR), and body size. RESULTS: Patients with lower eGFR and older age required significantly lower weekly doses of acenocoumarol. In the INR 2.00 - 3.00 group, males required higher doses than females, correlating with both greater body size and higher eGFR. However, in the INR 2.50 - 3.50 group, males and females received the same median dose despite differing body metrics, mirroring their similar renal function. A positive correlation was found between BSA-adjusted eGFR and weekly dose, particularly when eGFR exceeded 90 mL/min (Spearman r = 0.48, p = 0.0001). CONCLUSION: Renal function, as measured by BSA-adjusted eGFR, is a critical determinant of acenocoumarol dose requirements. These findings support the inclusion of renal function in future acenocoumarol dose calculators and emphasize the importance of individualized dosing strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcenocoumarolGlomerular Filtration RateAnticoagulantsInternational Normalized RatioKidneyPrecision MedicineHumansFemaleMaleAgedMiddle AgedAged, 80 and overAdultDrug MonitoringSex FactorsBody Surface AreaAge FactorsDrug Dosage CalculationsRetrospective Studies

Substanzen

AcenocoumarolAnticoagulants

Zitieren

APA

Farandzha, D., Velchev, V., & Hazarbasanov, D. (2025). Personalized management of acenocoumarol dosage using eGFR: Analysis of INR data in a cohort of 204 patients. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204882

Vancouver

Farandzha D, Velchev V, Hazarbasanov D. Personalized management of acenocoumarol dosage using eGFR: Analysis of INR data in a cohort of 204 patients. Int. Journal of Clinical Pharmacology and Therapeutics. 2025. doi:10.5414/cp204882

BibTeX
@article{Farandzha2025,
  author = {Farandzha, Dzhem and Velchev, Vasil and Hazarbasanov, Dobri},
  title = {Personalized management of acenocoumarol dosage using eGFR: Analysis of INR data in a cohort of 204 patients},
  journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
  year = {2025},
  doi = {10.5414/cp204882}
}
Kostenlos starten →